Get the Stockscreener App
22.52
4.55%
0.98
Immunome Inc stock is traded at $22.52, with a volume of 1.19M.
It is up +4.55% in the last 24 hours and down -14.73% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$21.54
Open:
$22
24h Volume:
1.19M
Relative Volume:
0.61
Market Cap:
$2.48B
Revenue:
$12.59M
Net Income/Loss:
$-212.39M
P/E Ratio:
-7.2991
EPS:
-3.0853
Net Cash Flow:
$-185.92M
1W Performance:
+1.72%
1M Performance:
-14.73%
6M Performance:
+129.80%
1Y Performance:
+150.78%
1-Day Range:
$21.62
$22.81
1-Week Range:
$21.20
$22.81
52-Week Range:
$5.1501
$27.65
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
22.52 | 2.38B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome (IMNM) TTM Net Loss Of US$212 Million Reinforces Bearish Profitability Narratives - simplywall.st
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing - AOL.com
IMNM: Stephens & Co. Lowers Price Target to $30, Maintains Overw - GuruFocus
Immunome (IMNM): Craig-Hallum Raises Price Target to $36.00 and - GuruFocus
Immunome (NASDAQ:IMNM) Price Target Raised to $36.00 - MarketBeat
Stephens Cuts Immunome (NASDAQ:IMNM) Price Target to $30.00 - MarketBeat
Decoding Immunome Inc (IMNM): A Strategic SWOT Insight - GuruFocus
Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus
Immunome 2025 Net Loss Narrows - marketscreener.com
Immunome (IMNM) Projects Strong Cash Position and Promising Drug Developments - GuruFocus
Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss - marketscreener.com
Immunome: Q4 Earnings Insights - Benzinga
IMNM: Net loss improved to $212.4M in 2025, with $653.5M cash supporting late-stage oncology pipeline - TradingView
Immunome (IMNM) 2025 10-K: Phase 3 varegacestat data and ADC pipeline - Stock Titan
Immunome (IMNM) posts 2025 loss but scores major Phase 3 cancer win - Stock Titan
Immunome Reports Full Year 2025 Financial Results and Provides Business Update - Business Wire
TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM - MarketBeat
IMNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors - simplywall.st
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Insider Monkey
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Immunome, Inc. (IMNM) Investor Outlook: Exploring a Promising 60% Upside in the Biotech Sector - DirectorsTalk Interviews
Private Capital Advisors Inc. Has $1.38 Million Stake in Immunome, Inc. $IMNM - MarketBeat
Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - Yahoo Finance
Immunome to Present at Upcoming March 2026 Investor Conferences - BioSpace
First Week of October 16th Options Trading For Immunome (IMNM) - Nasdaq
Immunome to Present at Upcoming Investor Conferences - The Joplin Globe
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% - Yahoo Finance
Risk Analysis: Is Immunome Inc part of any ETF2025 Year in Review & Technical Pattern Based Signals - baoquankhu1.vn
Immunome, Inc. $IMNM Shares Acquired by NEOS Investment Management LLC - MarketBeat
Immunome, Inc. (IMNM) - DirectorsTalk Interviews
Market Fear: Can Immunome Inc be the next market leaderShort Setup & Weekly Breakout Watchlists - baoquankhu1.vn
Is Immunome, Inc. (IMNM) the best booming stock to buy right now? - MSN
Jim Cramer on Immunome: "If you want to speculate on it, fine" - MSN
Should You Buy Immunome Inc (IMNM) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Redmile Group (IMNM) discloses 5.2% Immunome stake via managed funds - Stock Titan
Brokers Issue Forecasts for Immunome FY2025 Earnings - MarketBeat
Trading Systems Reacting to (IMNM) Volatility - Stock Traders Daily
Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses - MarketBeat
Immunome (NASDAQ:IMNM) Stock Rating Upgraded by HC Wainwright - MarketBeat
Institutional investors in Immunome, Inc. (NASDAQ:IMNM) see US$269m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
H.C. Wainwright initiates coverage on Immunome stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates coverage on Immunome stock with Buy rating - Investing.com Australia
How do insiders feel about Immunome Inc.Market Growth Summary & Daily Stock Trend Reports - mfd.ru
HC Wainwright Initiates Immunome at Buy With $40 Price Target - marketscreener.com
Immunome (IMNM) Initiates Coverage with a Buy Rating by HC Wainw - GuruFocus
Immunome (IMNM): Biotech minnow in the spotlight as volatility returns to cancer drug hunters - AD HOC NEWS
Principal Financial Group Inc. Buys 762,147 Shares of Immunome, Inc. $IMNM - MarketBeat
Candriam S.C.A. Buys 541,441 Shares of Immunome, Inc. $IMNM - MarketBeat
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 5, 2026 - BioSpace
Immunome reports inducement grants under Nasdaq listing rule - marketscreener.com
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):